Study of Progression of Community Acquired Pneumonia in the Hospital in Patients With More Severe Preexisting Diseases and Immunosuppression (PROGRESSCOMORB)

Study of Progression of Hospitalized Community Acquired Pneumonia - Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis in Patients With More Severe Preexisting Diseases and Immunosuppression to Complement the PROGRESS CAP Cohort

Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization. However, the course of disease of patients in the hospital remains hard to predict. While most patients will recover quickly, some will, despite appropriate treatment, develop a severe course leading to sepsis and systemic responses resulting in organ dysfunction. The PROGRESS consortium aims to identify clinical, genetic, and other molecular markers and combinations there of predicting a severe course of pneumonia in the hospital. Such predictors will, for instance, support decisions on earlier transfer of patients to intensive care and thus improving outcome. PROGRESS-COMORB aims to extend findings from the previous PROGRESS study to patients with more severe preexisting conditions and immunosuppression.

Study Overview

• Status: Recruiting
• Conditions: Pneumonia; Sepsis; Shock, Septic

Detailed Description

Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization. However, the course of disease of patients in the hospital remains hard to predict. While most patients recover quickly, others will, despite appropriate treatment, develop a severe course leading to sepsis and systemic responses resulting in organ dysfunction. The PROGRESS consortium aims to identify clinical, genetic and other molecular markers and combinations there of predicting a severe course of pneumonia in the hospital. Such predictors will, for instance, support decisions on earlier transfer of patients to intensive care and thus improving outcome. PROGRESS-COMORB aims to extend findings from the previous PROGRESS study to patients with more severe preexisting conditions and immunosuppression.

In this observational, longitudinal case-cohort study, patients are enrolled within 48 hours of hospitalization (within 7 days for patients directly admitted to intensive care) and patient's progress is followed in much detail for up to six days thereafter. Further data are collected until discharge from the hospital. Patients are followed up on at days 28, 180, and 360 after enrollment.

Baseline assessment comprises sociodemographic, anamnestic, family history, and life-style information. Upon enrollment, Pneumonia Severity Index (PSI) and CURB-65 are determined. For the day of enrollment, up to six subsequent study days routine laboratory and clinical observations and information on therapy are documented as well as data for determining the Sequential Organ Failure Assessment (SOFA) score, Systemic Inflammatory Response Syndrome (SIRS) status, and organ dysfunction. Starting with enrollment, up to four consecutive sets of biomaterials are collected comprising serum, plasma, and materials for extraction of RNA. Blood for extraction of DNA is collected once.

Follow up comprises vital status, housing situation, recurrence of pneumonia, stroke, myocardial infarction, occurrence of diabetes and a quality of life questionnaire.

In the PROGRESS consortium, the transition (progression) from uncomplicated community-acquired pneumonia acquired pneumonia (uCAP) to severe CAP (sCAP) to CAP with severe sepsis or septic shock or multiple organ failure (ssCAP) is investigated. Previous work of the PROGRESS consortium led to the successful identification of an operationalization for the severity of CAP and causal pathomechanistic correlations, a clinical prognosis score, the assignment of altered molecules to dysfunctions of the respiratory tract, kidneys, coagulation, cardiovascular system, and liver, and a gene expression signature for early detection of patients at risk of developing ssCAP.

For the translation of findings from the PROGRESS-CAP study into clinical applicability, their applicability to CAP patients with immunosuppression or with more severe preexisting conditions has to be confirmed.

• Study Type: Observational
• Enrollment (Estimated): 300

Contacts and Locations

• Study Contact: Name: Sarah Berger, MD; Phone Number: +49-30-450553347; Email: sarah.berger@charite.de
• Study Contact Backup: Name: Peter Ahnert, MD; Phone Number: +49-341-9716282; Email: peter.ahnert@imise.uni-leipzig.de

Study Locations

• Germany
  • Berlin, Germany, 13353
    • Recruiting
    • Charité - Universitätsmedizin Berlin, Medizinische Klinik m. S. Infektiologie und Pneumologie
  • Berlin, Germany, 14089
    • Recruiting
    • Gemeinschaftskrankenhaus Havelhöhe, Kardio-Pneumologie
  • Berlin, Germany, 13509
    • Recruiting
    • Humboldt-Klinikum Vivantes, Kardiologie und kons. Intensivmedizin
  • Dessau, Germany, 06847
    • Recruiting
    • Städtisches Klinikum Dessau, Innere Medizin
  • Hamburg, Germany, 20246
    • Recruiting
    • Universitätsklinikum Hamburg Eppendorf, Onkologisches Zentrum, Pneumologische Studienzentrale
  • Leipzig, Germany, 04129
    • Recruiting
    • Klinikum St. Georg gGmbH, Klinik für Infektions-/Tropenmedizin und Nephrologie
  • Leipzig, Germany, 04103
    • Recruiting
    • Universitätsklinikum Leipzig, Klinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie
  • Marburg, Germany, 35043
    • Recruiting
    • Universitätsklinikum Gießen und Marburg, Klinik für Pneumologie und Anästhesie
  • Münster, Germany, 48149
    • Recruiting
    • Universitätsklinikum Münster, Kardiologie 1
  • Rotenburg, Germany, 27356
    • Withdrawn
    • Diakoniekrankenhaus Rotenburg(Wümme)gGmbH, Zentrum für Pneumologie

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult patients hospitalized for treatment of community acquired pneumonia. Patients can be enrolled in general care, intensive care, and in emergency departments.

Description

Inclusion Criteria:

1. Hospitalization with community acquired pneumonia (CAP) confirmed by pulmonary infiltrate in chest imaging
2. Valid informed consent form
3. Working diagnosis of CAP by enrolling physician
4. No hospitalization for any reason within 28 days prior to hospitalization for the current episode of CAP

5. At least 2 out of the five following clinical symptoms:

   • Fever
   • Cough
   • Purulent sputum
   • Shortness of breath or need for respiratory support
   • Crackling or rales on auscultation, dullness to percussion, or bronchial breathing

6. At least 1 of the following criteria

   • Known HIV infection or AIDS
   • Anti-tumor treatment within the past six months
   • Therapy with corticosteroids ≥ 20mg for ≥ 14 days before enrollment
   • Non-steroidal immunosuppressive therapy within the past six months
   • Cytostatic therapy within the past six months
   • Radiation therapy within the past six months
   • Bone marrow transplant received
   • Respiratory support at home via tracheostoma
   • Cystic fibrosis
   • Heart failure: New York Heart Association (NYHA) Stadium IV or HFrEF (defined as left ventricular ejection fraction <40%).
   • Decompensated liver disease (Child-Pugh class C)
   • Diabetes mellitus with HbA1c ≥ 8,5 %
   • End-stage renal disease requiring dialysis
   • Pulmonary hypertension (all classes) with mPAP > 20 mmHg (right heart catheter)

Exclusion Criteria:

1. Participation in this study at an earlier time
2. More than 48 hours in the hospital before enrollment (for patients directly to intensive care: more than 7 days)
3. Pregnancy
4. Breastfeeding
5. Active tuberculosis
6. Acute lung injury or acute respiratory distress syndrome for extrapulmonary reasons
7. Massive aspiration
8. Sepsis with extrapulmonary focus
9. Acute pulmonary embolism

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Worst measure of disease severity	Disease severity is operationalized by the Sequential Organ Failure Assessment (SOFA-score).	Between enrollment and day six

Secondary Outcome Measures

Outcome Measure	Time Frame
All cause mortality	up to one year after enrollment
disease-specific mortality	up to one year after enrollment
duration of hospitalization	up to one year after enrollment
duration of intensive care treatment	up to one year after enrollment
duration of ventilator assisted breathing	up to one year after enrollment

Collaborators and Investigators

• Sponsor: Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps
• Collaborators: Charite University, Berlin, Germany; University of Leipzig; Jena University Hospital
• Investigators: Principal Investigator: Norbert Suttorp, MD, Charité Univerity, Berlin, Germany

Study record dates

Study Major Dates

• Study Start (Actual): February 28, 2022
• Primary Completion (Estimated): February 28, 2027
• Study Completion (Estimated): February 28, 2028

Study Registration Dates

• First Submitted: January 9, 2023
• First Submitted That Met QC Criteria: January 9, 2023
• First Posted (Actual): January 18, 2023

Study Record Updates

• Last Update Posted (Actual): March 13, 2024
• Last Update Submitted That Met QC Criteria: March 12, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: CAP; disease progression; community ascquired pneumonia
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Lung Diseases; Systemic Inflammatory Response Syndrome; Inflammation; Disease Attributes; Shock; Sepsis; Disease Progression; Shock, Septic; Pneumonia
• Other Study ID Numbers: PROGRESS-COMORB

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Anonymized individual participant data will be made available after conclusion of the study. Participants can apply for clinical and molecular study data by sending structured project proposals to the PROGRESS board. The PROGRESS board will evaluate proposals for scientific quality, adherence to the limits set by patient's informed consent statements and by intellectual property regulations of the funding agency. Proposals shall not be denied without concrete reason.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No